#### ASSESSMENT OF PESTES DES PETIT RUMINANTS (PPR) INFECTION IN CAMELS AND THEIR ROLE IN EPIDEMIOLOGY OF PPR

#### **INVESTIGATOR:** Irene Nafula Ogali BVM, MSc



Dr George Gitao<sup>1</sup>(BVM, MSc, PhD) Dr Binepal Yatinder Singh<sup>2</sup>(BVM, MSc, PhD) Prof Gathumbi P.K.<sup>1</sup> (BVM, MSc, PhD) Dr. Wamwayi M. Henry<sup>3</sup> (BVM, MSc, PhD)

<sup>1</sup>Department of Veterinary Pathology, Microbiology and Parasitology, University of Nairobi

<sup>2</sup>Animal Biotechnology and Diagnostics, National Agriculture Research Laboratories, Kenya Agriculture Research Institute

<sup>3</sup>African Union Inter-African Bureau for Animal Resources

**PRESENTATION FORMAT** 

- I. Background
- **II.** Objectives
- **III. Materials and methods**
- IV. Work plan
- V. Budget



# BACKGROUND

# What is PPR?

- Highly contagious viral disease
- High mortality (50-80%)
- Primarily of small ruminants
- Disease resembles rinderpest






# **MANIFESTATION**

high fever, ocular and nasal discharge, pneumonia, severe diarrhoea





# **PPRV DISTRIBUTION**

Lineage III

Lineage IV

Lineage I

Lineage II

Widely distributed across sub-Saharan Africa, Arabia, the Middle East and Asia.


Has potential to spread to Europe and other free countries

(Dhar et al., 2002; Banyard et al., 2010)


Positive serology Free of PPR



## **PPRV DISTRIBUTION**








#### Kenya status-2008




# **PPRV DISTRIBUTION**



#### **Current status (FAO,2009)**





#### BACKGROUND

#### **PPR CONSEQUENCES**

#### **Healthy herd**












#### Diagnosis



#### **ELISA LAB**



Immunohistochemistry



#### **Virus isolation**

**Competitive ELISA** 




Apply bound antibody/antigen complexes to coated well



**C-ELISA** 





#### **i-ELISA**

Specific DNA product (372)

A B A **PCR** 

#### **Transmission**

PPRV is highly labile

Contact- main mode of transmission

Discharges from eyes, nose and mouth & loose faeces, contain large amounts of virus



#### Control

# Livestock movement control and immunization of the susceptible flocks

- Rinderpest tissue culture vaccine
- Homologous PPR vaccine is used (Diallo et al., 2007)
- PPR recombinant marker vaccines
- Thermostable vaccine developed & being piloted in various countries (Silva et al 2014)



#### Immunity

Humoral and cell-mediated immune responses (Sinnathamby et al 2001)

Recovered & vaccinated animals develop strong, specific, long-term protective immunity

Maternal antibodies persist 3-4 months in lambs or kids



#### Host range







Primarily disease of sheep and goats but has been reported in other wild and domestic species







#### Host range



 Of importance disease of sheep and goats seems to be 'emerging' in camels











PPR is similar to RINDERPEST
 =complicates global eradication of rinderpest

- PPR is emerging in new areas, spread fast.
- Control is tantamount
- Proper control rely on proper knowledge of disease



- Many hosts other than primary hosts susceptible; disease not understood in these hosts
- Of particular interest is the camelid spp in which PPR seems to have 'emerged'
- Role of camels in the epidemiology of PPRV has not been adequately elaborated.



- Pathogenesis & progression of PPR in camels poorly understood.
- OIE suggests camels may be considered for vaccination in control of PPR; therefore need for development of experimental model/parameters
- In Kenya, PPR is still poorly understood, more so viral circulation in-btwn outbreaks; other domestic animals may be involved including camels, therefore need to understand role of other animals including camels.



- A PPRV isolate obtained from Turkana during 2006 outbreak & been successfully used in experimental infection of sheep and goats
- Will be used in trial in camels & needs propagation for future vaccine efficacy trials & host-virus interaction studies.
- Its also important to use an isolate from the Sudan which has reported disease in camels (lineage 4)



### **Objectives**

# Main Objective

# To assess PPR infection in camels and the possible role of camels in the epidemiology of PPRV

#### Specific Objective

- To determine the in-vitro growth characteristics and infectivity of the Kenyan vs Sudan PPRV isolate
- To determine and compare the clinico-pathological features of Kenyan and Sudan PPRV isolates infection in the camel
- To quantify viral tires in secretions and investigate the possible role of camels in transmission of PPRV to in contact small ruminants.
- To determine the exposure level of PPR in camels in Kenya.



# Specific objective 1 Cells and virus

- Kenyan & Sudan isolate of PPRV
- Lamb kidney, BHK and Vero cells

## In vitro infection

- Grind animal tissue (kept at -70°C) from previous experiment
- Prepare 10% homogenate in MEM
- Infect cultured cells with supernatant
- 30min adsorption at 37°C, incubated and harvest at different times pi

# Specific objective 1 Cells and virus

- Kenyan & Sudan isolate of PPRV
- Lamb kidney, BHK and Vero cells

## In vitro infection

- Grind animal tissue (kept at -70°C) from previous experiment
- Prepare 10% homogenate in MEM
- Infect cultured cells with supernatant containing PPRV
- 30min adsorption at 37°C, incubated and harvest at different times pi

Materials and Methods
Specific objective 1
Flow cytometry
Harvest cells

- Immunolabel with anti-N monoclonal & stain with isotype specific mouse antisera (IgG) conjugated with fluorescein isothiocyanate
- Growth of PPRV in cells by cytopathic effect



Materials and Methods Specific objective 1

# **Virus infectivity assay**

Cell and supernatant fractions from PPR infected and non-infected cultures will be harvested at different times pi.

Infected culture will be titrated to determine the viral load per ml



# **Specific objective 2 Experimental trial**

- 19 Camels (8m-1yr) –acclamatize 1 month-Fed on hay, pellets, housed at isolated unit (VRC)
- 3 months

#### **Challenge protocol 5 camels**

- Camel 1 different inoculation routes, 10 ml of PPRV inoculum: 2.5 ml SC, 2.5ml I.V & 5 ml intranasally
- 2. Camel 2- Orally 10 ml of PPRV inoculums
- 3. Camel 3 10ml intranasal spray
- 4. Camel 4 infected I.V with 5ml/Intraocular 5 ml
- 5. Camel 5 uninfected control



**Specific objective 2 Experimental trial** 

<u>Challenge protocol 4 camels-</u> •Infection with different doses 3 camels •10<sup>5</sup>-10<sup>7</sup> TCID<sub>50</sub>/ml •I control

<u>Clinico-pathological analysis</u> 10 camels **1.Group 1** – Kenyan Isolate(4 camels) **2.Group 2**- Sudan Isolate (4 camels) 3.Group 3-Control (2 Camels)



**Specific objective 2** 

#### **Experimental trial**

- Observe animals twice daily (rectal temp and other C/S-(RP,PR,GIT)
- Collect Oro-pharyngeal (Ph), ocular (Oc) and nasal (Ns) swabs, EDTA whole blood daily.
- Blood for seroconversion studies and blood count studies.



## **Specific objective 2**


#### **Experimental trial**

- Camels with severe disease to be euthanized and PM done. Collect lung, lymph node and spleen.
- Seek approval of the Animal welfare committee, KARI-Muguga
- PPRV tissue tropism- histology, immunohistochemistry and RT-PCR



#### **Specific objective 3**

**Quantification of virus in camel discharges by RT-PCR** 



- Extract RNA from oronasal swabs & other discharges, using RNeasy Mini kit
- Primers specific to PPRV
- Analyse amplicon by electrophoresis
- Quantify RNA by spectrophotometry



Materials and Methods
Specific objective 3

**Quantification of virus in camel discharges by RT-PCR** 

One absorbance unit at 260 nm wavelength equals 40 µg RNA per ml

Concentration of RNA will be compared in different secretions



## **Specific objective 3**

# **Transmission to in-contact goats**

6 small stock : 2 controls( 3-goat,3-sheep: 5-6 months) housed with PPR infected camels and monitored daily for clinical signs, pathology for 1 month

Collect Oro-pharyngeal (Ph), ocular (Oc) and nasal (Ns) swabs & blood for virus detection

Post-mortem examination on infected goats.



**Specific objective 4** 

Study of exposure level of PPR in camels in Kenya

Obtain 380 camel serum DVS, Kabete and TRC, KARI. The samples have been collected over the years as part of camel disease surveillance.

They include samples from North Eastern and Eastern Kenya among others.

Antibody levels against PPRV in camels will be determined using c-ELISA.



## Workpan

Activity in the yearly quarters	2014			2015			2016					
	1	2	3	4	1	2	3	4	1	2	3	4
PPR literature review, proposal writing												
Finalize the proposal												
Study of PPR exposure levels in camels												
PPRV culture and propagation												
Set up challenge protocol in camel												
Experimental trial in camels												
Quantify PPRV RNA in camel												
discharges/secretions												
Expose goats to infected camels												
Sample analysis, Data entry and analysis												
Thesis write up												
Thesis submission and defense												102000

# **Budget**

Activity items			
	Unit	Time	Total
		(months)	Costs
PPR literature review, proposal writing	1	4	38,600
Study of PPR exposure levels in camels	1	5	373,950
PPRV culture and propagation	1	5	524,000
Set up challenge protocol in camels	1	1	357,000
Experimental trial in camels	1	4	1,367,000
Quantify PPRV RNA in camel discharges/secretions	1000	5	767,880
Expose goats to infected camels	5	2	110,000
Sample analysis, Data entry and analysis	1	12	150,000
Thesis write up	1	2	10,000
Total			3,688,430



